The Filing Desk

Orchestra BioMed vs Stereotaxis

Orchestra BioMed OBIO · Stereotaxis STXS · Health Care Equipment

Orchestra BioMed reported revenue of $34 million in fiscal 2025, about the same as Stereotaxis' $32 million in fiscal 2025. Orchestra BioMed's revenue grew 1169.2% in its latest year, and Stereotaxis' grew 20.3%. Orchestra BioMed had an operating margin of -154.7%, against -68.3% at Stereotaxis. Free cash flow was −$49 million at Orchestra BioMed and −$14 million at Stereotaxis.

Side by side

Orchestra BioMedStereotaxis
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$34M$32M
Revenue growth1,169.2%20.3%
Revenue growth a year, last 5 years—4.0%
Gross margin99.4%52.7%
Operating margin−154.7%−68.3%
Net margin−157.4%−66.8%
Free cash flow−$49M−$14M
Free cash flow margin−147.7%−42.5%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count29.7%6.8%
Last close$7.00$1.01
P/E at the last close——
Insider trades, last 12 monthsbought $259,541, sold $257,682bought $135,754, sold $0
Piotroski F-score5 of 9—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Orchestra BioMedStereotaxis
Operating margin
Percent of revenue
Orchestra BioMedStereotaxis
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Orchestra BioMedStereotaxis

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Orchestra BioMed and Stereotaxis pages.